• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human E3 ubiquitin-protein ligase makorin-1 (MKRN1)

ACP10813

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP10813 Target NameMKRN1
FormLyophilized powderExpression SystemCustom Production. Please inquire and provide the desire expression system.
Expression Range1-482Protein LengthFull length protein
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ9UHC7
Background Information
  • Uniprot Id

    Q9UHC7

  • Target Species

    Human

  • Target Name

    MKRN1

  • Target Full Name

    E3 ubiquitin-protein ligase makorin-1

  • Target Function

    E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include FILIP1, p53/TP53, CDKN1A and TERT. Keeps cells alive by suppressing p53/TP53 under normal conditions, but stimulates apoptosis by repressing CDKN1A under stress conditions. Acts as a negative regulator of telomerase. Has negative and positive effects on RNA polymerase II-dependent transcription.

  • Target Tissue Specificity

    Ubiquitous.

  • Target Research Area

    Cell Biology

  • Target Synonyms

    E3 ubiquitin-protein ligase makorin-1; FLJ21334; HGNC:7112; Makorin; Makorin ring finger protein 1; MKRN 1; mkrn1; MKRN1_HUMAN; OTTHUMP00000212117; OTTHUMP00000212118; OTTHUMP00000212121; OTTHUMP00000212124; Ring finger protein 1; RING finger protein 61; RNF61

Inquire Recombinant Human E3 ubiquitin-protein ligase makorin-1 (MKRN1) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification